LifeStream Balloon Expandable Vascular Covered Stent
Bard Peripheral Vascular, Inc. · Decision date Sep 29, 2025
What did the FDA decide?
FDA records P160024/S014 as a supplement to PMA P160024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 29, 2025.
FDA approval order statement
an additional manufacturing facility for the stent covering process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 29, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160024/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- PRL
- Decision code
- OK30
- Decision date
- Sep 29, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Iliac covered stent, arterial.
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- PRL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160024/S014 received
Application receipt date recorded by FDA.
P160024/S014 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160024. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code PRL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Oct 8, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jun 16, 2026 | FDA | |
iCast Covered Stent SystemP120003/S007 | Atrium Medical Corp. | PMA supplement | May 13, 2026 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | Feb 5, 2026 | FDA | |
iCast Covered Stent SystemP120003/S009 | Atrium Medical Corp. | PMA supplement | Dec 22, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bard Peripheral Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1625 W. 3rd St., Tempe, AZ, 85281
Sources and methodology
- Original FDA record: P160024/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



